ANPCF (CelLBxHealth) Ending Cash Position: $3.83 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CelLBxHealth Ending Cash Position?

CelLBxHealth ANPCF Ending Cash Position is $3.83 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

CelLBxHealth's Ending Cash Position for the quarter that ended in Jun. 2026 was $3.83 Mil.

CelLBxHealth's quarterly Ending Cash Position increased from Jun. 2025 ($7.15 Mil) to Dec. 2025 ($9.84 Mil) but then declined from Dec. 2025 ($9.84 Mil) to Jun. 2026 ($3.83 Mil).

CelLBxHealth's annual Ending Cash Position declined from Dec. 2023 ($20.53 Mil) to Dec. 2024 ($13.18 Mil) and declined from Dec. 2024 ($13.18 Mil) to Dec. 2025 ($9.84 Mil).

CelLBxHealth Ending Cash Position Related Terms

CelLBxHealth Ending Cash Position Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Ending Cash Position Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.34 38.85 20.53 13.18 9.84

CelLBxHealth Semi-Annual Data
Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.75 13.18 7.15 9.84 3.83

CelLBxHealth Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CelLBxHealth's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=13.956+-4.118
=9.84

CelLBxHealth's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=9.799+-5.966
=3.83

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $3.83 Mil mean?
CelLBxHealth (ANPCF) has a Ending Cash Position of $3.83 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's Ending Cash Position too high?
CelLBxHealth's current Ending Cash Position is $3.83 Mil.
How does CelLBxHealth's Ending Cash Position compare to TMO and DHR?
CelLBxHealth's Ending Cash Position of $3.83 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current Ending Cash Position is $3.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (ANPCF) has a current Ending Cash Position of $3.83 Mil. The current Ending Cash Position is $3.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For CelLBxHealth (ANPCF), the current Ending Cash Position is $3.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges CLBX:UKDWV:Germany
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.